MARY CROWLEY CANCER RESEARCH ADDS RODNEY OLSEN TO BOARD OF DIRECTORS
Mary Crowley Cancer Research (MCCR) announced today the addition of Rodney Olsen to their Board of Directors.
Archive for Press Releases
MARY CROWLEY CANCER RESEARCH ADDS ED MARX TO BOARD OF DIRECTORS
Mary Crowley Cancer Research (MCCR) announced today the addition of Edward Marx to their Board of Directors.
NEW TRIALS AT MARY CROWLEY CANCER RESEARCH
The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling (for example through blockade of the androgen receptor, or inhibition of testosterone production).
A MESSAGE FROM CHAIRMAN OF THE BOARD ROY LAMKIN
The health and safety of the patients at Mary Crowley Cancer Research is always our top priority.
RUNWAY FOR HOPE: LYNN LENTSCHER’S SPEECH
The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th.
BE THE DIFFERENCE FOUNDATION ANNOUNCES RUNWAY FOR HOPE
DALLAS, Texas – Join Be the Difference Foundation for their inaugural luncheon and fashion show, Runway for Hope, benefitting Mary Crowley Cancer Research,
TEMPUS AND MARY CROWLEY JOIN FORCES TO TAKE ON LUNG CANCER
Tempus is a Chicago-based leading technology company that is ushering precision medicine as a means to advance cancer care.
ANNOUNCING ASHLEY E. ROSS, M.D., PHD
The Board of Mary Crowley Cancer Research is delighted to announce the appointment of Ashley E. Ross, M.D., PhD, as Executive Medical Director.
FDA APPROVES FIRST CANCER TREATMENT FOR ANY SOLID TUMOR WITH A SPECIFIC GENETIC FEATURE
FDA approves first cancer treatment for any solid tumor with a specific genetic feature
EWING SARCOMA TRIAL
Mary Crowley Cancer Research has opened a new Phase I clinical trial for advanced Type 1 Ewing sarcoma, a rare bone cancer affecting children, adolescents, and young adults.